Using a new generation of TILs therapy to treat solid tumors, “Jinfeng Biotechnology” completed a pre-A round of financing of 10 million US dollars

It is reported that “Jinfeng Biotechnology” has recently completed a pre-A round of financing of 10 million US dollars. The investors in this round of financing are mainly Hanye Capital and Hongli Venture Capital, and the funds raised will be mainly used for the upgrade of the “Jinfeng Biotechnology” technology platform, the construction of the patent pool and related team building.

“Jinfeng Bio” is a research and development company of tumor cell therapy products, committed to combining the R&D and application of non-invasive tumor detection and screening in the field of precision cell therapy, using bioinformatics and artificial intelligence technology to deeply mine tumor multi-omics data, optimize cell therapy strategies, and improve the effectiveness of tumor treatment. The company’s angel investor is Professor Brendan Lee, an academician of the American Academy of Sciences and head of the Department of Genetics at Baylor College of Medicine, who is currently serving as a scientific advisor to WindBio.

Image from Pixabay

The core of the technology of “Jinfeng Bio” is tumor infiltrating lymphocyte (TIL), which is a new type of anti-tumor effector cell. Different from general immune cells, the immune cells of TIL come from tumor tissue, which determines that the screened TILs have a very strong ability to recognize tumor-related antigens, and can accurately migrate to tumors in situ after being expanded back into patients in vitro, and effectively kill tumor cells.

“Jinfeng Bio” TILs therapy first uses bioinformatics and AI technology-assisted gene sequencing technology to determine the specific mutation information in the patient’s tumor cells, and then uses the mutation information to find the T cells that can most effectively target these mutations, and finally extracts and enriches these T cells to achieve the purpose of accurately identifying and killing tumor cells. According to reports, the therapy is safer than CAR-T cell therapy, and the future development track is wide, “lung cancer, non-small cell cancer, colorectal cancer, breast cancer, cervical cancer are all the direction that TILs therapy is trying to overcome.”

Dr. Yu Fuli, founder and CEO of “Vigorous Biotechnology”, graduated from Baylor College of Medicine under the tutelage of Professor Richard Gibbs, academician of the National Academy of Sciences and genomics titan, and obtained a doctorate degree in molecular genetics, and completed postdoctoral research at Harvard University Medical School under Professor David Reich, a population geneticist and paleoanthropal geneticist. After that, he worked at the Human Genome Sequencing Center of the Department of Genetics, Baylor College of Medicine, USA, and participated in and led a number of major international human genome projects. He also served as the Chief Information Officer of Berry Genomics, where he was responsible for overall bioinformatics analysis, product development, and the application of artificial intelligence technology in genomics.

The founding team also includes bioinformatics statistics experts in the field of tumor multiomics research, well-known pharmaceutical companies in the field of cell therapy, and cell experts with rich front-line practical experience in R&D, preparation and clinical application. Yu Fuli said: “I hope that our products can combine genetic testing, cooperate with upstream companies doing second-generation sequencing technology, and closely contact with downstream companies that research cell therapy products, go to the clinical treatment end, and produce a complete product.” ”

Editor: Cai Shuning

About the Author

You may also like these